Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581729 | 0.81 | ATR (0.45) | HDAC8HDAC6GPR119 | |
| SCHEMBL3956297 | 0.76 | AAK1 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3957883 | 0.74 | VCP (0.58) | USP30 | |
| SCHEMBL3654119 | 0.73 | USP30 (0.48) | GPR119USP30 | |
| SCHEMBL28430951 | 0.70 | CA12 (0.47) | HDAC6CA12CA1CA2CA9 | |
| SCHEMBL6350965 | 0.68 | CA12 (0.71) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4522505 | 0.68 | DKK1 (0.44) | HDAC8HDAC6DYRK1ACA12 | |
| SCHEMBL2119508 | 0.67 | TP53 (0.53) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL21056008 | 0.67 | CA12 (0.50) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL30436074 | 0.67 | CA12 (0.50) | GPR119CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009034390-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |